Dr. Michael Har-Noy Says That The Battle Against Cancer Is Being Lost

20 Jul

Dr. Michael Har-Noy, CEO of Immunovative Therapies, a biotech company started in Israel in 2004, says that we are losing the fight against cancer. Dr. Michael Har-Noy indicates that over the past 3 decades, the incidence of cancer has increased markedly, affecting about one out of every three females and one out of every two males.. This means that the present rate of occurrences of new cancer cases is 50% higher in men and 25% higher in women than in the previous generation. The National Cancer Institute predicts that, because of our increasingly elderly population, the number of new malignancy cases will almost double by the year 2050.

Dr. Michael Har-Noy says that despite years of clinical research, decreases in mortality from cancer have been minimal, and significant reductions in death rates are primarily due to decreases in lung cancer deaths secondary to less smoking in the population, and not from real advances in cancer therapies. Also, Dr. Michael Har-Noy notes that the total five-year survival rate of about 50% for all cancer cell types is virtually the same as it was in 1970.

Conventional cancer treatments have extremely negative emotional and physical effects on patients. Many feel that the treatment is worse than the disease. The financial burden that cancer therapies place on our culture is profound.  Dr. Michael Har-Noy says that the direct annual cost of cancer therapy has almost quadrupled over the past 20 years. It has grown from about $18 billion in 1985 to $41 billion in 1995, and then to an immense $80 billion in 2005. Dr. Michael Har-Noy adds that in 1999, indirect costs from tax increases, wage losses, reduction in overall productivity secondary to cancer was a staggering $100 billion.

At Immunovative Therapies, Ltd., Dr. Michael Har-Noy synthesizes unique biologic drugs that stimulate one’s own immune system to attack malignant cells. Preliminary results of a Phase I/II trial show remarkable efficacy of these drugs against many different tumor cell types. Pivotal randomized Phase II/III trials of these new therapies are being planned.

%d bloggers like this: